Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

TS03 Inc Trust Units TSTIF



GREY:TSTIF - Post by User

Post by bossuon Aug 14, 2019 8:29am
172 Views
Post# 30026183

In the News Globe says Loe moves TSO3 to ''tender from buy'

In the News Globe says Loe moves TSO3 to ''tender from buy'

TSO3 Inc (C-TOS) - In the News

 

Globe says Loe moves TSO3 to "tender" from "buy"

2019-08-14 08:02 ET - In the News 
Shares issued 93,564,808
TOS Close 2019-08-13 C$ 0.42

The Globe and Mail reports in its Wednesday, Aug. 14, edition that Echelon Wealth Partners analyst Douglas Loe is not keen on Stryker's offer for TSO3, but nonetheless has moved his call on the shares to "tender" from "buy." The Globe's David Leeder writes in the Eye On Equities column that Mr. Loe says the bid is "modest" in several ways. He removed his share target, which was previously $1.25. Analysts on average target the shares at 90 cents. Mr. Loe says in a note: "Though the Stryker offer is clearly below our previous PT, it does seem reasonable to us within the context of TSO3's recent revenue/EBITDA performance and when considering that TSO3's flagship technology has long benefited from all of the positive FDA regulatory regard that we expected to drive sales, and actual sales performance has not caught up to the technology in this circumstance. Although it is difficult to predict with certainty if any alternative offers could be forthcoming, our best guess is that interest in the firm has been widely solicited across multiple hospital sterilization equipment and endoscope reprocessing firms, many of which are aware of VP4 through prior alliances. ... We believe we are justified in shifting our rating."


<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse